The abnormal activation of STAT3 has been shown to be closely related to chemotherapy resistance in bladder cancer [36], blood cancer [37], glioma [38], ovarian cancer [39], breast cancer [40] and acute myeloid leukemia [41]. Here, STAT3 is linked to hematopoietic and lymphoid system neoplasm.